Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05256641|
Recruitment Status : Recruiting
First Posted : February 25, 2022
Last Update Posted : March 13, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Diffuse Large B-Cell Lymphoma High-grade B-cell Lymphoma Transformed Lymphoma Secondary Central Nervous System Lymphoma||Drug: Acalabrutinib||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse|
|Actual Study Start Date :||January 23, 2023|
|Estimated Primary Completion Date :||January 30, 2024|
|Estimated Study Completion Date :||January 30, 2025|
Experimental: Group I (acalabrutinib)
Beginning day 90, patients receive acalabrutinib PO QD and then PO BID once no longer on prophylactic antifungal (CYP34A inhibitors) until day 365 in the absence of disease progression or unacceptable toxicity.
Experimental: Group II (acalabrutinib)
Beginning day 60, patients receive acalabrutinib PO QD and then PO BID from day 74 if there are no dose reductions until day 365 in the absence of disease progression or unacceptable toxicity.
Experimental: Group III (acalabrutinib)
Beginning anytime between days 28-104, patients receive acalabrutinib PO BID until day 365 in the absence of disease progression or unacceptable toxicity.
- Permanent discontinuation of acalabrutinib [ Time Frame: Up to 12 months from cellular therapy ]Tolerability will be determined by the number of patients who permanently discontinue acalabrutinib within 12 months from cellular therapy due to intolerance. The proportion of patients with acalabrutinib discontinuation will be reported along with 95% and 90% confidence intervals.
- Progression-free survival (PFS) [ Time Frame: At 12 months from cellular therapy ]The 1-year PFS will be evaluated based on progression of disease per Lugano criteria or death, and will be reported based on Kaplan-Meier estimates along with 95% confidence interval.
- PFS [ Time Frame: Up to 5 years ]Will be reported based on 95% confidence intervals at annual time points.
- Overall survival [ Time Frame: Up to 5 years ]Time from cellular therapy to death due to any cause, assessed at 1 and 5 years based on Kaplan-Meier estimates along with 95% confidence interval
- Rate of conversion from partial response following chimeric antigen receptor (CAR) T-cell therapy to complete response after the addition of acalabrutinib maintenance [ Time Frame: Up to day 365 ]Will be reported based on 95% confidence intervals.
- Incidence of dose reductions, interruptions, or discontinuations of acalabrutinib based on the protocol criteria [ Time Frame: Up to day 365 ]Will be reported based on 95% confidence intervals.
- Incidence of graft versus host disease (GvHD) >= stage 2 [ Time Frame: Up to day 365 ]Based on the Mount Sinai Acute GVHD International Consortium criteria for acute GvHD and the National Institutes of Health consensus criteria for chronic GvHD. Will be reported based on 95% confidence intervals.
- Incidence of hematologic adverse events [ Time Frame: Up to day 365 ]Based on Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. Will be reported based on 95% confidence intervals.
- Incidence of non-hematologic adverse events [ Time Frame: Up to day 365 ]Based on CTCAE v5.0. Will be reported based on 95% confidence intervals.
- CAR T-cell persistence [ Time Frame: Up to 5 years ]CAR T-cell persistence measured by mass cytometry upon enrollment, 90 days after initiation of acalabrutinib, and at time of relapse.
- Immunophenotyping of peripheral blood mononuclear cells [ Time Frame: Up to 5 years ]Types and numbers of proteins present on the leukemia cell surface via mass cytometry upon enrollment, 90 days after initiation of acalabrutinib, and at time of relapse
- Intracellular cytokine and phospho-protein profiling of peripheral blood mononuclear cells [ Time Frame: Up to 5 years ]Types of proteins involved in cell signaling in leukemia cells via mass cytometry upon enrollment, 90 days after initiation of acalabrutinib, and at time of relapse.
- Acalabrutinib metabolite [ Time Frame: At 1-3 weeks after initiation of acalabrutinib ]Acalabrutinib metabolite detected in the cerebral spinal fluid at 1-3 weeks after initiation of acalabrutinib in participants with history of secondary central nervous system lymphoma.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Ages 18-70 years
One of the following:
Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for:
- High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc
- Large B-cell lymphoma with a history of secondary CNS involvement
- Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia
- High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis
- Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma
- Eastern Cooperative Oncology Group (ECOG) 0-2
Requirements for post-ASCT and post-alloHCT participants:
- Disease status of partial response (PR) or complete response (CR) prior to transplantation
- Receive reduced-intensity conditioning regimen
- Enrollment no later than day +90
Requirements for post-CAR T-cell therapy participants:
- Disease status of PR or CR after post-CAR T-cell therapy positron emission tomography (PET)-computed tomography (CT) at 1-3 months
- Enrollment no later than day +104
- Ability to give full informed consent
- Female subjects who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib
- Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty
- Absolute neutrophil count (ANC) > 500/uL (microliters)
- Platelets > 50,000/uL independent of transfusions
- Hemoglobin > 8 g/dL independent of transfusions
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
- Total bilirubin =< 1.5 x ULN, unless directly attributable to Gilbert's syndrome
- Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) =< 1.8 mg/dL
- Cord blood as donor source in alloHCT
- New York Heart Association Class III or IV
- Left ventricular ejection fraction < 50%
- Estimated glomerular filtration rate < 30 mL/min
- Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors and unable to replace with equivalent medication
- Acute or chronic graft-versus-host disease (GvHD) >= stage 3 at time of enrollment
- Received packed red blood cells (pRBC) transfusion within the past 2 weeks
- Received platelet transfusion within the past 1 week
- Active invasive fungal infection
- Active bacterial or viral infection until resolution of the infection
- History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)
- Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug
- Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug
- Refractory nausea and vomiting, inability to swallow the formulated product, or malabsorption syndrome; chronic gastrointestinal disease, gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment
- Received a live virus vaccination within 28 days of first dose of study drug
- Known history of infection with human immunodeficiency virus (HIV)
- History of bleeding diathesis (e.g., hemophilia, von Willebrand disease)
- Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
- Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited
- Breastfeeding or pregnant
- Concurrent participation in another therapeutic clinical trial
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05256641
|Contact: Vlad Kustanovitch||310-206-5756||VKustanovich@mednet.ucla.edu|
|United States, California|
|UCLA / Jonsson Comprehensive Cancer Center||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Vlad Kustanovich 310-206-5756 VKustanovich@mednet.ucla.edu|
|Principal Investigator: Caspian Oliai, MD|
|University of California Davis Comprehensive Cancer Center||Recruiting|
|Sacramento, California, United States, 95817|
|Contact: Joseph M. Tuscano 916-734-3772 email@example.com|
|Principal Investigator: Joseph M. Tuscano|
|United States, Oklahoma|
|University of Oklahoma||Not yet recruiting|
|Oklahoma City, Oklahoma, United States, 73190|
|Contact: Matthew J. Wieduwilt 405-217-8001 Matthew-Wieduwilt@ouhsc.edu|
|Principal Investigator: Matthew J. Wieduwilt|
|Principal Investigator:||Caspian Oliai, MD||UCLA / Jonsson Comprehensive Cancer Center|
|Responsible Party:||Jonsson Comprehensive Cancer Center|
|Other Study ID Numbers:||
NCI-2021-12421 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
|First Posted:||February 25, 2022 Key Record Dates|
|Last Update Posted:||March 13, 2023|
|Last Verified:||March 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Immune System Diseases